CLEC2D

Across TCGA pan-cancer cohorts, CLEC2D Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CLEC2D data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CLEC2D Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLEC2D expression acts as an unfavorable survival marker.

BLCA, COAD, and UCEC are the cancer types where CLEC2D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.212	0.720	.007	12	view →
COAD	OS	Median	All	0.168	0.806	.002	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BRCA	OS	Median	All	0.181	0.579	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CLEC2D–BLCA (OS)

Open the BLCA breakdown →